Chinese Medical Device Disruption War: Who Will Lead the Rise and Fall of the Thirteen Major Segmented Markets?-Shuntai Kang Yuan-Focusing on medical beds and supplies

language

Home

Chinese Medical Device Disruption War: Who Will Lead the Rise and Fall of the Thirteen Major Segmented Markets?

2025-09-08

In the first half of 2025, China's medical device industry will show significant differentiation under multiple pressures of deepening centralized procurement, medical insurance cost control, and international trade fluctuations, and an unprecedented market restructuring is quietly taking place.

In the first half of 2025, China's medical device industry will face unprecedented challenges. 131 medical device companies on the A-share market achieved a total operating revenue of 118.817 billion yuan, a year-on-year decrease of 4.29%; The net profit attributable to the parent company was 18.812 billion yuan, a year-on-year decrease of 17.17%.
Industry differentiation is becoming increasingly evident: revenue from high-value consumables increased by 3.99%, becoming a rare highlight; Medical equipment revenue decreased by 5.84%; The field of in vitro diagnostics has significantly decreased by 15.72%.
Against the backdrop of policies such as volume based procurement and medical insurance cost control, the medical device industry is undergoing structural adjustments. The performance varies greatly in different segmented fields, and innovation and going global have become key choices for enterprises to break through difficulties.

Despite significant overall progress in domestic medical devices, the high-end market is still dominated by foreign brands. Siemens and GE hold a 53% share in the global high-end medical imaging equipment market; 76% of minimally invasive surgeries in top tier hospitals in China are performed by Da Vinci robots.
In the laparoscopic market, data from the first half of 2025 shows that two foreign companies, KARL STORS and Olympus, have captured nearly 50% of the market share. Karl Storz's market share surged from 26.36% in 2024 to 37.08%, firmly holding the top spot in the market.
The five key areas of foreign hegemony include high-end medical imaging equipment, minimally invasive surgical robots, cardiovascular intervention instruments, in vitro diagnostic equipment, and home medical equipment. The technological barriers in these fields are high, requiring long-term technical accumulation and clinical data validation.

None